Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Grupo Espanol De Tumores Neuroendocrinos
Sponsor

Grupo Espanol De Tumores Neuroendocrinos

Spain Calle De Velazquez 7 Planta 3, 28001 Madrid, Spain

About the sponsor

Research activity includes advanced radioactive-iodine-refractory differentiated thyroid carcinoma and anaplastic thyroid carcinoma, with interest in therapies directed at TROP-2 and cabozantinib in thyroid cancer.

  • Differentiated thyroid carcinoma
  • Anaplastic thyroid carcinoma
  • TROP-2-targeted therapy
  • Biomarkers in thyroid cancer

The sponsor also supports work on predictive blood-based markers and treatment response assessment in advanced thyroid malignancies.

About Specializations

Grupo Espanol De Tumores Neuroendocrinos runs clinical trials in conditions such as Neuroendocrine carcinoma, Small intestine neuroendocrine tumour, Anaplastic thyroid cancer, Neuroendocrine tumour, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Small intestine neuroendocrine tumour

Recruiting

Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) oxodotreotide
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Anaplastic thyroid cancer

Recruiting

Study on Sacituzumab Govitecan for Patients with Advanced Differentiated and Anaplastic Thyroid Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Neuroendocrine tumour+1

Recruiting

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Neuroendocrine carcinoma

Not recruiting

Study of tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Neuroendocrine carcinoma

Not recruiting

Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Thyroid cancer

Not recruiting

Study on Cabozantinib for Patients with Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.